Medicamen Biotech Limited (MEDICAMEQ.BO)
INR 492.5
(6.9%)
INR 492.5
(6.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 160.31 Million INR | 370.98% |
| 2022 | 34.03 Million INR | -84.51% |
| 2021 | 219.71 Million INR | 47.17% |
| 2020 | 149.28 Million INR | 52.93% |
| 2019 | 97.61 Million INR | 121.62% |
| 2018 | 44.04 Million INR | 161.68% |
| 2017 | -71.41 Million INR | -145.32% |
| 2016 | 157.58 Million INR | -11.9% |
| 2015 | 178.87 Million INR | -10.81% |
| 2014 | 200.54 Million INR | 39.03% |
| 2013 | 144.23 Million INR | -13.82% |
| 2012 | 167.37 Million INR | 55.18% |
| 2011 | 107.85 Million INR | 196.68% |
| 2010 | 36.35 Million INR | -68.3% |
| 2009 | 114.67 Million INR | 45.48% |
| 2008 | 78.82 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 160.31 Million INR | 19.38% |
| 2023 Q3 | 134.28 Million INR | -13.87% |
| 2023 Q2 | 155.91 Million INR | -24.96% |
| 2023 FY | 160.31 Million INR | 370.98% |
| 2023 Q1 | 207.78 Million INR | 510.44% |
| 2022 Q2 | -20.61 Million INR | -153.89% |
| 2022 FY | 34.03 Million INR | -84.51% |
| 2022 Q3 | 305.5 Million INR | 1582.08% |
| 2022 Q4 | 34.03 Million INR | -88.86% |
| 2022 Q1 | 38.24 Million INR | -82.59% |
| 2021 Q4 | 219.71 Million INR | 484.93% |
| 2021 Q3 | 37.56 Million INR | -82.42% |
| 2021 Q2 | 213.68 Million INR | 449.23% |
| 2021 Q1 | 38.9 Million INR | -73.94% |
| 2021 FY | 219.71 Million INR | 47.17% |
| 2020 Q1 | 30.92 Million INR | -68.32% |
| 2020 FY | 149.28 Million INR | 52.93% |
| 2020 Q4 | 149.28 Million INR | 371.77% |
| 2020 Q3 | 31.64 Million INR | -79.15% |
| 2020 Q2 | 151.76 Million INR | 390.7% |
| 2019 Q4 | 97.61 Million INR | 84.92% |
| 2019 Q3 | 52.78 Million INR | 13297.25% |
| 2019 FY | 97.61 Million INR | 121.62% |
| 2019 Q2 | -400 Thousand INR | -100.47% |
| 2019 Q1 | 85.19 Million INR | 93.41% |
| 2018 Q3 | 123.01 Million INR | 234.32% |
| 2018 Q2 | -91.58 Million INR | -140.28% |
| 2018 Q1 | 227.34 Million INR | 418.37% |
| 2018 FY | 44.04 Million INR | 161.68% |
| 2018 Q4 | 44.04 Million INR | -64.19% |
| 2017 Q3 | 56.41 Million INR | -65.46% |
| 2017 Q1 | 30.38 Million INR | -80.72% |
| 2017 Q4 | -71.41 Million INR | -226.59% |
| 2017 FY | -71.41 Million INR | -145.32% |
| 2017 Q2 | 163.31 Million INR | 437.42% |
| 2016 Q2 | 105.15 Million INR | 284.33% |
| 2016 FY | 157.58 Million INR | -11.9% |
| 2016 Q1 | 27.36 Million INR | -84.7% |
| 2016 Q3 | 36.64 Million INR | -65.15% |
| 2016 Q4 | 157.58 Million INR | 330.0% |
| 2015 Q2 | 166.91 Million INR | 621.32% |
| 2015 Q4 | 178.87 Million INR | 566.85% |
| 2015 Q1 | 23.14 Million INR | -88.46% |
| 2015 Q3 | 26.82 Million INR | -83.93% |
| 2015 FY | 178.87 Million INR | -10.81% |
| 2014 Q3 | 25.46 Million INR | -81.08% |
| 2014 FY | 200.54 Million INR | 39.03% |
| 2014 Q4 | 200.54 Million INR | 687.49% |
| 2014 Q2 | 134.56 Million INR | 392.75% |
| 2014 Q1 | 27.31 Million INR | -81.07% |
| 2013 Q1 | 21.12 Million INR | -87.38% |
| 2013 Q3 | 20.8 Million INR | -85.7% |
| 2013 Q4 | 144.23 Million INR | 593.19% |
| 2013 FY | 144.23 Million INR | -13.82% |
| 2013 Q2 | 145.47 Million INR | 588.75% |
| 2012 Q2 | 142.18 Million INR | 0.0% |
| 2012 FY | 167.37 Million INR | 55.18% |
| 2012 Q4 | 167.37 Million INR | 0.0% |
| 2011 FY | 107.85 Million INR | 196.68% |
| 2011 Q4 | 107.85 Million INR | 0.0% |
| 2010 FY | 36.35 Million INR | -68.3% |
| 2009 FY | 114.67 Million INR | 45.48% |
| 2008 FY | 78.82 Million INR | 0.0% |
| 2008 Q4 | 78.82 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 95.853% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 95.659% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 105.64% |
| Granules India Limited | 9.28 Billion INR | 98.274% |
| Indoco Remedies Limited | 6.47 Billion INR | 97.525% |
| Achyut Healthcare Limited | -3.74 Million INR | 4379.658% |
| Ajanta Pharma Limited | -954.9 Million INR | 116.789% |
| Alkem Laboratories Limited | -1.6 Billion INR | 109.961% |
| Alpa Laboratories Limited | 35.36 Million INR | -353.344% |
| Brooks Laboratories Limited | 49.48 Million INR | -223.969% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 103.198% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 95.14% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 113.847% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 98.758% |
| Eris Lifesciences Limited | 13.8 Billion INR | 98.839% |
| FDC Limited | -57.75 Million INR | 377.594% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 103.741% |
| Gufic Biosciences Limited | 3.19 Billion INR | 94.981% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 103.86% |
| Ipca Laboratories Limited | 11.41 Billion INR | 98.596% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 111.534% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 91.706% |
| Lasa Supergenerics Limited | 205.79 Million INR | 22.101% |
| Laurus Labs Limited | 24.38 Billion INR | 99.343% |
| Lupin Limited | 17.19 Billion INR | 99.068% |
| Mankind Pharma Limited | -9.9 Billion INR | 101.618% |
| Medico Remedies Limited | 78.67 Million INR | -103.765% |
| Megasoft Limited | 1.28 Billion INR | 87.529% |
| NATCO Pharma Limited | -5.81 Billion INR | 102.756% |
| Piramal Pharma Limited | 42.27 Billion INR | 99.621% |
| RPG Life Sciences Limited | -364.7 Million INR | 143.958% |
| Sigachi Industries Limited | 859.94 Million INR | 81.357% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 100.221% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -10.581% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -246.922% |
| Unichem Laboratories Limited | 931.91 Million INR | 82.797% |
| Wanbury Limited | 1.1 Billion INR | 85.503% |
| Windlas Biotech Limited | -273.04 Million INR | 158.715% |
| ZIM Laboratories Limited | 983.6 Million INR | 83.701% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 95.902% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 117.022% |
| Divi's Laboratories Limited | -39.77 Billion INR | 100.403% |
| Hester Biosciences Limited | 2.29 Billion INR | 93.002% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 106.828% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 164.438% |
| Bal Pharma Limited | 1.26 Billion INR | 87.312% |
| Strides Pharma Science Limited | 23.25 Billion INR | 99.311% |
| Venus Remedies Limited | -267.7 Million INR | 159.886% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 93.862% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 97.396% |
| Shilpa Medicare Limited | 9.06 Billion INR | 98.232% |
| Aarti Drugs Limited | 5.54 Billion INR | 97.111% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 114.557% |
| Suven Life Sciences Limited | -1.63 Billion INR | 109.819% |
| Ind-Swift Limited | 9.5 Billion INR | 98.314% |
| Valiant Laboratories Limited | -295.03 Million INR | 154.339% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 94.317% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 98.401% |
| Themis Medicare Limited | 764.96 Million INR | 79.043% |
| Hikal Limited | 7.96 Billion INR | 97.988% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 99.496% |
| Sequent Scientific Limited | 4.17 Billion INR | 96.163% |
| Novartis India Limited | -5.89 Billion INR | 102.721% |
| Wockhardt Limited | 18.27 Billion INR | 99.123% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 99.408% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 969.11% |
| Neuland Laboratories Limited | -214.05 Million INR | 174.894% |
| Morepen Laboratories Limited | -231.17 Million INR | 169.349% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -33.553% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 83.571% |